Literature DB >> 6286325

Pharmacological profiles of beta-funaltrexamine (beta-FNA) and beta-chlornaltrexamine (beta-CNA) on the mouse vas deferens preparation.

S J Ward, P S Portoghese, A E Takemori.   

Abstract

The profiles of action of beta-funaltrexamine (beta-FNA) and beta-chlornaltrexamine (beta-CNA) have been assessed in the mouse vas deferens preparation. beta-FNA, but not beta-CNA, demonstrated a reversible agonist action that appeared to be mediated via kappa-receptor interaction. beta-CNA produced an irreversible antagonism of mu-, kappa- and delta-mediated agonist actions, whereas beta-FNA irreversibly antagonized mu-mediated agonist effects only. This selective action of beta-FNA could also be seen following administration in vivo. beta-CNA and particularly beta-FNA should prove valuable in the elucidation of multiple opioid receptors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6286325     DOI: 10.1016/0014-2999(82)90083-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

1.  Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.

Authors:  Yunyun Yuan; Saheem A Zaidi; Orgil Elbegdorj; Lindsey C K Aschenbach; Guo Li; David L Stevens; Krista L Scoggins; William L Dewey; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2013-11-07       Impact factor: 7.446

2.  Synthesis and Pharmacology of a Novel κ Opioid Receptor (KOR) Agonist with a 1,3,5-Trioxazatriquinane Skeleton.

Authors:  Shigeto Hirayama; Naohisa Wada; Toru Nemoto; Takashi Iwai; Hideaki Fujii; Hiroshi Nagase
Journal:  ACS Med Chem Lett       Date:  2014-06-26       Impact factor: 4.345

3.  Opioids increase potassium conductance in submucous neurones of guinea-pig caecum by activating delta-receptors.

Authors:  S Mihara; R A North
Journal:  Br J Pharmacol       Date:  1986-06       Impact factor: 8.739

4.  Differential effect of stimulation strength in mouse vas deferens on inhibition of neuroeffector transmission by receptor type selective opioids.

Authors:  D Ramme; P Illes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-01       Impact factor: 3.000

5.  Proceedings of the British Pharmacological Society. University of Dundee, 11th-14th September, 1984. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1984-12       Impact factor: 8.739

6.  Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.

Authors:  Yi Zheng; Samuel Obeng; Huiqun Wang; Abdulmajeed M Jali; Bharath Peddibhotla; Dwight A Williams; Chuanchun Zou; David L Stevens; William L Dewey; Hamid I Akbarali; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2019-01-11       Impact factor: 7.446

7.  Involvement of delta-opioid receptors in the effects of morphine on locomotor activity and the mesolimbic dopaminergic system in mice.

Authors:  M Narita; T Suzuki; M Funada; M Misawa; H Nagase
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Multiple opiate receptors in the guinea pig enteric nervous system: unmasking the copresence of receptor subtypes.

Authors:  A R Gintzler; D Hyde
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

9.  Cloning and bioinformatics of amphibian mu, delta, kappa, and nociceptin opioid receptors expressed in brain tissue: evidence for opioid receptor divergence in mammals.

Authors:  Craig W Stevens; Christopher M Brasel; Shekher Mohan
Journal:  Neurosci Lett       Date:  2007-04-11       Impact factor: 3.046

Review 10.  Opioid research in amphibians: an alternative pain model yielding insights on the evolution of opioid receptors.

Authors:  Craig W Stevens
Journal:  Brain Res Brain Res Rev       Date:  2004-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.